XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration
XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.
Overview
Investors seeking healthcare exposure must choose between the stability of diversified pharmaceutical giants and the high-growth potential of specialized biotech firms.
The State Street Health Care Select Sector SPDR ETF (NYSEMKT:XLV) provides broad exposure to the healthcare sector at a lower cost, while the iShares Biotechnology ETF (NASDAQ:IBB) focuses on a more volatile niche.
Details
This comparison analyzes how these different focuses affect cost, yield, and risk-adjusted performance for long-term holders.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.